4//SEC Filing
Pizzie Nick 4
Accession 0000950170-25-021716
CIK 0001579428other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 9:20 PM ET
Size
14.8 KB
Accession
0000950170-25-021716
Insider Transaction Report
Form 4
Pizzie Nick
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-13$3.50/sh+12,000$42,000→ 54,187 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-14$3.50/sh−3,000$10,500→ 0 totalExercise: $3.50From: 2019-05-16Exp: 2028-05-16→ Common Stock (3,000 underlying) - Sale
Common Stock
2025-02-13$129.86/sh−12,000$1,558,320→ 42,187 total - Exercise/Conversion
Common Stock
2025-02-14$3.50/sh+3,000$10,500→ 45,187 total - Sale
Common Stock
2025-02-14$131.07/sh−3,000$393,210→ 42,187 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-13$3.50/sh−12,000$42,000→ 0 totalExercise: $3.50From: 2019-05-16Exp: 2028-05-16→ Common Stock (12,000 underlying)
Holdings
- 488(indirect: See explanation 6 below.)
Common Stock
Footnotes (6)
- [F1]Represents an exercise of stock options which was held for 7 years and exercised prior to the 10 year expiration date of such options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $128.50 and $131.64.
- [F5]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $130.06 and $131.72.
- [F6]Represents additional shares indirectly beneficially owned by the reporting person as custodian for his children's UTMA accounts.
Documents
Issuer
Axsome Therapeutics, Inc.
CIK 0001579428
Entity typeother
Related Parties
1- filerCIK 0001742143
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 9:20 PM ET
- Size
- 14.8 KB